A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant.

Trial Profile

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Ezetimibe/simvastatin; Simvastatin
  • Indications Cardiovascular disorders; Dyslipidaemias; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms HPS2-THRIVE
  • Most Recent Events

    • 25 Mar 2013 Adverse events of this trial are reported to be consistent with those in the AIM-HIGH trial (niacin extended-release monotherapy), according to the University of Oxford media release.
    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology. Additional information taken from slides presented at the conference.
    • 09 Mar 2013 Unexpected adverse event rates (bleeding and infections) reported in an American College of Cardiology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top